SCHEMBL16610943

SCHEMBL16610943

O=c1[nH]cc(Cl)c2c1c(-c1ccc(CN3CCOCC3)cc1)nn2-c1c(F)cccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 1/20 0.42
HRH3 Q9Y5N1 2/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TNKS O95271 1/20 0.39
GPR84 Q9NQS5 3/20 0.39
CHEK1 O14757 1/20 0.39
NTRK1 P04629 1/20 0.39
ALOX5 P09917 1/20 0.38
DCTPP1 Q9H773 1/20 0.38
PIK3CD O00329 1/20 0.38
PIK3R2 O00459 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PIK3CG P48736 1/20 0.38
PIK3R5 Q8WYR1 1/20 0.38
PIK3R3 Q92569 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16611103 0.89 KDM4E (0.43) TNKSNTRK1ALDH1A1KDM4EHPGD
Hydrochloric Acid SCHEMBL16611325 0.88 KDM4E (0.43) TNKSNTRK1ALDH1A1KDM4EHPGD
SCHEMBL16611076 0.87 CYP2A13 (0.39) CYP2A13RAB9ANPC1TP53SMN1; SMN2
SCHEMBL16611740 0.86 LTA4H (0.37) LMNAALDH1A1KDM4EHPGD
SCHEMBL16611193 0.85 PDGFRB (0.42) TNKSNTRK1ALDH1A1KDM4EHPGD
SCHEMBL16610908 0.85 DCTPP1 (0.35) DCTPP1MEN1KMT2AALDH1A1
SCHEMBL16611173 0.85 ALOX5 (0.41) HRH3TNKSCHEK1NTRK1ALOX5
SCHEMBL16611245 0.84 GRIA2 (0.39) HRH3NTRK1
SCHEMBL16610669 0.82 CNR2 (0.48) RAB9ANPC1NTRK1
SCHEMBL16611258 0.81 KCNJ5 (0.35) NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 CYP2A13 2454/4885HRH3 3535/4885RAB9A 2162/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 CYP2A13 2454/4885HRH3 3535/4885RAB9A 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.